#039;000 5,000 4,000 3,000 2,000 1,000 Sales 0 Revenue (1,000) (2,000) NPAT (3,000) FY2004 FY2005 FY2006 FY2007 FY2008 FY2

Slide 6: FY13 Results to Date: H1 Revenue

FY13 RESULTS TO DATE For personal use only H1 REVENUE $6.14m Clinical trials revenue was $5.8 million or 94% Axon Sports revenue $0.27 million, up from $0.08 million pcp • Concussion testing revenue $0.14 million, up from $0.08 million • Cognitive training represents new revenue stream in H1 - $0.13

Slide 7: FY13 Results to Date: Contracted Clinical Trial Revenue

FY13 RESULTS TO DATE For personal use only CONTRACTED CLINICAL TRIAL REVENUE - AN IMPORTANT INDICATOR FOR FY13 RESULTS Clinical Trials Revenue FY13 FY12 H1 Recognised Revenue $5.80m $6.86m H2 Revenue contracted at 31-Dec $4.75m $3.79m Total contracted revenue for FY as at 31-Dec $10.55m $10.65m FY13

Slide 8: FY13 Results to Date: H1 Net Loss

FY13 RESULTS TO DATE For personal use only H1 Net Loss $0.49m, in line with guidance Clinical Trials contribution $2.94 Axon Sports net expenditure ($0.60) Healthcare establishment costs ($0.27) Other costs, including central resources ($2.45) Tax Expense ($0.11) NPAT ($0.49)

Slide 9: Financial Summary and Major Shareholders

FINANCIAL SUMMARY For personal use only Cash position at 31 December 2012 $4.3m Trade receivables $2.5m Total liabilities ($1.6m)…no debt MAJOR SHAREHOLDERS Martyn Myer (Chairman) 19.34% Rudy Chapa (Non-exec) 17.00% Chris Abbott 9.80% Charles Goode 5.83%

Slide 10: Cognigram

COGNIGRaAM Ajuo esn feuosied JOS

Slide 11: Significant New Revenue Stream

Healthcare For personal use only SIGNIFICANT NEW REVENUE STREAM The management of Alzheimer’s disease will become one of the biggest health care issues in the future A new report predicts AD patients in the USA alone will triple by 2050 to 13.8m people The increase in the incidence of AD will strain

Slide 12: Cogstate Strengths

Healthcare For personal use only COGSTATE STRENGTHS • Independent of language and culture • Shown to be sensitive to change associated with AD and MCI • Simple to use with clear results allowing doctors to track change over time • Extensive consultation with physicians to ensure ease of use • Initia

Slide 13: What Is Cognigram?

WHAT IS COGNIGRAM"? A simple computerized battery of tests based on a card game’ ap Designed to detect cognitive impairment COGNIGRamM and monitor change over time in cognitive function’” Validated in numerous AD studies’” COGNITIVE DOMAINS EVALUATED/TASKS & © © Ay UMMC CMe Detection: Is it there? V

Slide 14: Overview of AD and Other Dementias: Aging Population

XK [ OVERVI EW OF AD AND OTHER DEMENTIAS THE CANADIAN POPULATION IS AGING An estimated 5 million Canadians were 65 years of age or older in 2011 - a number expected to double in the next 25 years to reach 10.4 million in 2036. By 2051, approximately one in four Canadians will be 65 or over.* PREVALE

Slide 15: Overview of AD and Other Dementias: Risk Factors

\ OVERVI EW OF AD AND OTHER DEMENTIAS RISK FACTORS FOR DEVELOPING AD> © Non-modifiable Advancing age MCI First-degree relative with AD Presence of the e4 form of the gene apolipoprotein E Head trauma and brain injury © Modifiable Cardiovascular disease risk factors, such as physical inactivity, high

Slide 16: Importance of Early Diagnosis of AD

LL. ~ IMPORTANCE OF EARLY DIAGNOSIS OF AD so nseosuem EARLY DETECTION OF DEMENTIA... ACCORDING TO THE CANADIAN INSTITUTES © Means patients and caregivers can access treatment, OF HEALTH RESEARCH (CIHR) 2010:’ education, counselling, and other services in a timely fashion so as to:* Delay decline ’ ’

Slide 17: Cognigram Administration

~ COGNIGRAM" — ADMINISTRATION ADMINISTRATION PROCESS op F Doctor i PATIENT DATA COMPUTED _ \ J A ON COGNIGRAM™ SERVER __ TESTING» CENTRES

Slide 18: Cognigram Administration: Testing Centre

[ G COGSTAaTE COGNIGRAM" | ADMINISTRATION TESTING CENTRE WILL PROVIDE: * Patient appointment within 5 business days A favourable environment for patients Real-time results emailed or faxed to the referring physician PATIENT SUPERVISED BY QUALIFIED PERSONNEL OR A CERTIFIED NURSE “Fees may apply for p

Slide 19: Why Recommend Cognigram?

~ WHY RECOMMEND COGNIGRAM"? COGNIGRAM™ helps you monitor your concerned and at-risk patients’ cognitive function earlier, so you can provide treatment options at the appropriate time. Strongly supported by evidence?” Highly sensitive and proven in many neuropsychiatric and neurodegenerative disorder

Slide 20: Details of Rollout

DETAILS OF ROLLOUT For personal use only • First tests have been received • Priced at CAD$125 per test • Over 150 physicians have expressed interest in referring patients for testing • Now available in 8 testing centres in large Canadian cities • Full Canadian distribution expected by the end of 201

Slide 21: Clinical Trials

C.L.UN | C.A.L BBR: IA Tes

Slide 22: Clinical Trials

CLINICAL TRIALS For personal use only • Customers are pharma and biotech companies wanting to quantify the effect of their drugs • Full service offering, from consulting on design of clinical trial through to statistical analysis of data and final report and everything in between • Accounts for 95+%

Slide 23: Clinical Trial Customers

CLINICAL TRIAL CUSTOMERS: For personal use only

Slide 24: Clinical Trials – Business Update

CLINICAL TRIALS – BUSINESS UPDATE For personal use only • Significant sales resources added in FY12 allowing key scientist, Dr Paul Maruff to focus on Cognigram as well as overseeing all sales activities • $10.59m of future revenue contracted as at 31-Dec…$4.75m to be recognised in H2 FY13 • US$9m o

Slide 25: Axon Sports

For personal use only Axon Sports Confidential

Slide 26: Axon Sports: Protect and Train the Athletic Brain

AXON SPORTS For personal use only PROTECT AND TRAIN THE ATHLETIC BRAIN CONCUSSION MANAGEMENT COGNITIVE TRAINING Striving to convert elite acceptance to Authentication by high profile, well revenue growth driven by amateur respected programs to drive adoption of adoption apps Current elite users: Cur

Slide 27: For personal use only

For personal use only

Cogstate — Investor Presentation (March 2013) on 6ix

6ix — News, calls and decks from 54,000 public companies

News releases, calls, decks and charts for 54,000 public companies in one place, with 6ix AI and an email when your companies put out news. Free for investors.

Please enable JavaScript to use all features of 6ix.com.